AVB 101
Alternative Names: AVB-101; AVB-PGRN; AVB-PGRN (AVB-101)Latest Information Update: 11 Oct 2024
Price :
$50 *
At a glance
- Originator AviadoBio
- Class Antidementias; Gene therapies
- Mechanism of Action Gene transference; Progranulin protein replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Frontotemporal dementia
Most Recent Events
- 08 Oct 2024 Astellas Pharma and AviadoBio enter into an exclusive option and license agreement for AVB 101
- 28 Jul 2024 Pharmacodynamics data from a preclinical studies in frontotemporal dementia presented at the Alzheimers Association International Conference (AAIC-2024)
- 06 Nov 2023 AVB 101 receives Fast track status from the US FDA for Frontotemporal dementia